Intellia Therapeutics (NASDAQ:NTLA) Earns Neutral Rating from Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reiterated by Wedbush in a report released on Monday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush’s target price indicates a potential downside of 26.93% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Canaccord Genuity Group cut their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, June 3rd. Wolfe Research raised Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Chardan Capital reaffirmed a “buy” rating and set a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Guggenheim dropped their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. Finally, Barclays dropped their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.95.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $9.58 on Monday. The business’s 50 day moving average is $8.19 and its two-hundred day moving average is $9.74. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.18. The stock has a market capitalization of $992.30 million, a P/E ratio of -1.83 and a beta of 2.14.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analysts’ expectations of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company’s quarterly revenue was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.12) earnings per share. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC lifted its holdings in shares of Intellia Therapeutics by 3.8% during the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after purchasing an additional 474,629 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Intellia Therapeutics by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after purchasing an additional 561,978 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $43,177,000. Geode Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after purchasing an additional 45,930 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after purchasing an additional 970,700 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.